Throughout the last decades, vaccination has been key to prevent and eradicate 23 infectious diseases. However, many pathogens (e.g. Respiratory Syncytial Virus 24 (RSV), Influenza, Dengue and others) have resisted vaccine development efforts, 25 largely due to the failure to induce potent antibody responses targeting conserved 26 epitopes. Deep profiling of human B-cells often reveals potent neutralizing antibodies 27 that emerge from natural infection, but these specificities are generally subdominant 28 (i.e., are present in low titers). A major challenge for next-generation vaccines is to 29 overcome established immunodominance hierarchies and focus antibody responses 30 on crucial neutralization epitopes. Here, we show that a computationally designed 31 epitope-focused immunogen presenting a single RSV site targeted by Palivizumab 32 elicits superior site II epitope-specific responses compared to the RSV prefusion 33
Introduction 39
The development of vaccines has proven to be one of the most successful medical 40 interventions to reduce the burden of infectious diseases (1), and their correlate of 41 protection is the induction of neutralizing antibodies (nAbs) that block infection (2) . 42
43
In recent years, advances in high-throughput B-cell technologies have revealed a 44 plethora of potent nAbs for different pathogens which have resisted the traditional 45 means of vaccine development for several decades, including HIV-1 (3), Influenza (4), 46
Respiratory Syncytial Virus (RSV) (5, 6), Zika (7, 8), Dengue (9) and others (10-12). A 47 major target of these nAb responses is the pathogens fusion protein, which drives the 48 viral and host cell membrane fusion while undergoing a conformational rearrangement 49 from a prefusion to a postfusion state (13) . Many of these nAbs have been structurally 50 characterized in complex with their target, unveiling the atomic details of neutralization 51 epitopes (7, 14, 15) . Together, these studies have provided comprehensive antigenic 52 maps of the viral fusion proteins which delineate epitopes susceptible to antibody-53 mediated neutralization and provide a roadmap for rational and structure-based 54 vaccine design approaches. 55 56
The conceptual framework to leverage neutralizing antibody-defined epitopes for 57 vaccine development is commonly referred to as reverse vaccinology (16, 17) . 58
Although reverse vaccinology-inspired approaches have yielded a number of exciting 59 advances in the last decade, the design of immunogens that elicit such focused 60 antibody responses remains challenging. Successful examples of structure-based 61 immunogen design approaches include conformational stabilization of RSVF in its 62 prefusion state, which induces superior serum neutralization titers when compared to 63 immunization with F in the postfusion conformation (18). In the case of Influenza, 64 several epitopes targeted by broadly neutralizing antibodies (bnAbs) were identified 65 within the hemagglutinin (HA) stem domain, and an HA stem-only immunogen elicited 66 a broader neutralizing antibody response than full-length HA (19, 20) . Commonly, 67 these approaches have aimed to focus antibody responses on specific conformations 68 or subdomains of viral proteins. In a more aggressive approach, Correia et al. RSV, among other pathogens, strikingly illustrates the major need to be able to elicit 74 epitope-focused antibody responses. While the reasons for the failure of 1960's 75 formalin-inactivated RSV vaccine are not fully clear, several reports have suggested 76 that the induction of antibodies targeting non-neutralizing and structurally altered 77 neutralization epitopes may have played a role in the disease enhancement observed 78 upon later infection (22) (23) (24) . Despite more than 50 years of intensive research, a 79 licensed vaccine has remained elusive, and RSV-induced severe lower respiratory 80 tract infections continue to cause more than three million hospitalizations annually 81 (25). Thus far, the only prophylactic therapy for individuals at high risk for severe RSV 82 disease is passive immunization with Synagis®, a monoclonal antibody targeting 83 antigenic site II of RSVF (25) . 84
85
The absence of a potent and long-lasting immune response upon natural infection is 86 a major challenge associated with RSV, Influenza virus and other pathogens. While 87 single exposure to pathogens like Poliovirus confers life-long immunity, RSV, 88
Influenza and other pathogens have developed mechanisms to subvert the 89 development of a durable and potent neutralizing antibody response, thereby allowing 90 such pathogens to infect humans repeatedly throughout their lives (26). One of the 91 major factors hindering the induction of long-lasting protection after the first infection 92 is related to the antibody specificities induced. Upon exposure to the pathogen, the 93 human antibody responses predominantly target non-neutralizing or strain-specific 94 antigenic sites, whereas potent bnAbs are subdominant (27). This phenomenon is 95 generally referred to as B-cell immunodominance, which describes the unbalanced 96 immunogenicity of certain antigenic sites within an antigen, favoring strain-specific, 97 variable, non-neutralizing epitopes to the detriment of conserved, neutralization-98 sensitive epitopes (28). The factors that determine the antigenicity of specific epitopes 99 remain unclear, making the categorization of immunodominant and subdominant 100 epitopes an empirical classification based on serological analysis. Importantly, the 101 presence of high levels of antibodies directed against immunodominant epitopes can 102 sterically mask surrounding subdominant epitopes that may be targeted by bnAbs, 103 preventing the immune system from mounting productive antibody responses against 104 subdominant epitopes, and potentially limiting vaccination efficacy (27) (28) (29) (30) . 105
106
The immunodominance hierarchy is established within the germinal center, where B-107 cells undergo a binding affinity-based competition for available antigen and 108 subsequently initiate a clonal expansion stage, ultimately becoming long-lived plasma 109 cells or memory B-cells (31). Controlling this competition and driving antibody 110 responses towards the increased recognition of subdominant, neutralizing epitopes is 111 of primary importance to enable development of novel vaccines to fight pathogens 112 which have resisted traditional strategies. One of the few strategies to guide antibody 113 maturation was tested in the HIV field and is referred to as germline targeting, which 114 relies upon the activation and expansion of rare but specific B-cell lineages in naïve 115 individuals (32, 33). In contrast, under conditions of pre-existing immunity acquired 116 during natural infection or previous vaccination, the challenge is to manipulate already 117 Here, we investigate whether, under conditions of pre-existing immunity, a 130 computationally designed immunogen presenting a single epitope is able to reshape 131 serum antibody responses towards increased recognition of a specific neutralizing 132 epitope. For these studies, we used an optimized formulation and resurfaced version 133 of the previously designed RSV site II epitope-scaffold targeted by the monoclonal 134 antibody Palivizumab (21), the only FDA-approved prophylactic measure against RSV 135 infection. 136
137
We show that an optimized, multivalent presentation of an RSV antigenic site II 138 scaffold elicits superior levels of epitope-specific antibodies compared to prefusion 139 RSVF in naïve mice, indicating that the immunodominance of a particular epitope can 140 be altered through its presentation in a distinct molecular context. We further used the 141 site II scaffold as a boosting immunogen in animals primed with prefusion RSVF, 142 mimicking a scenario of pre-existing immunity against RSVF. Whereas homologous 143 boosting immunizations with prefusion RSVF failed to increase site II-specific 144 antibodies, we found that heterologous boosts with an epitope scaffold nanoparticle 145 enhanced serum responses towards this bona fide vaccine target, and that the 146 boosted antibodies neutralized RSV in vitro. For the first time, we provide compelling 147 evidence that synthetic immunogens comprising a single epitope can efficiently 148 enhance subdominant neutralizing antibody responses in vivo and redirect 149 specificities in bulk antibody responses. Such a strategy may present an important 150 alternative for pathogens where future vaccines are required to reshape pre-existing 151 immunity and elicit finely tuned antibody specificities. 152
Results 153 154
Design of an RSV-based nanoparticle displaying a site II epitope-focused immunogen 155
In a previous study, a computationally-designed, RSV site II epitope-scaffold 156 nanoparticle was shown to elicit serum neutralization activity in non-human primates 157 (NHPs) (21). Despite the fact that very potent monoclonal antibodies were isolated 158 from the immunized NHPs, the neutralization potency at serum level was modest, 159 indicating low titers of the potent antibodies. Therefore, our first aim was to take the 160 best previously tested immunogen (FFL_001) and further optimize the immunogen 161 delivery and immunization conditions to maximize the induction of site II-specific 162 antibodies. A comparative study of four different adjuvants revealed that Alhydrogel®, 163 an adjuvant approved for human use, yielded highest overall immunogenicity and 164 elicited antibodies cross-reactive with prefusion RSVF in four out of five mice 165 ( Supplementary Fig. 1 ). 166
167
Next, we sought to develop an improved, easily produced nanoparticle to multimerize 168 the epitope-scaffold for efficient B-cell receptor crosslinking. Previously, Correia et al. 169 (21) employed a chemical conjugation strategy of FFL_001 to a Hepatitis-B core 170 antigen based nanoparticle, which resulted in a difficult construct with a laborious 171 purification process. Recently, several studies have reported the use of RSV 172 nucleoprotein (RSVN) as a nanoparticle platform for immunogen presentation (39, 40) . 173
When expressed in E. coli, RSVN forms nanorings, 17 nm in diameter, containing 10 174 or 11 RSVN protomers (41). We reasoned that RSVN would be an ideal particle 175 platform to multimerize an RSV epitope scaffold, as RSVN contains strong, RSV-176
directed T-cell epitopes (40). However, our initial attempts to genetically fuse FFL_001 177 to RSVN yielded poorly soluble proteins that rapidly aggregated after purification. We 178 therefore employed structure-based protein resurfacing (42), attempting to improve 179 the solubility of this site II epitope-scaffold when arrayed in high density on RSVN. To 180 guide our resurfacing design process, we leveraged information from a sequence 181 homolog of the ribosomal recycling factor (PDB: 1ISE), the structural template 182 originally used to design FFL_001. Based on a sequence alignment of the mouse 183 homolog (NCBI reference: NP_080698.1) and FFL_001, we exchanged the FFL_001 184 amino acids for the mouse sequence homolog and used Rosetta Fixed Backbone 185 Design (43) to ensure that the mutations were not energetically unfavorable, resulting 186 in 38 amino acid substitutions (34.2% overall). We named this variant FFLM, whose 187 expression yields in E. coli showed a five-fold increase when compared to FFL_001, 188
and it was confirmed to be monomeric in solution ( Supplementary Fig. 2) . 189
190
To confirm that the resurfacing did not alter the epitope integrity, we measured the 191 binding affinities of FFLM to Motavizumab, a high-affinity variant of Palivizumab (44), 192
and to a panel of human site II nAbs previously isolated (5) using surface plasmon 193 resonance (SPR). All antibodies bound with high affinity to FFLM, indicating broad 194 reactivity of this immunogen with a diverse panel of human nAbs (Figure 1b) . 195
Interestingly, the tested nAbs showed approximately one order of magnitude higher 196 affinity to the epitope-scaffold as compared to prefusion RSVF, suggesting that the 197 epitope is properly presented and likely further stabilized in a relevant conformation. NRM enhances the induction of site II-specific antibodies 228
We next tested the immunogenicity of the site II scaffold nanoring and its ability to elicit 229 site II-specific antibodies. Three groups of ten mice were subjected to three 230 immunizations with 10 µg of NRM, monomeric FFLM and prefusion RSVF (45), which 231 is currently the leading immunogen for an RSV vaccine (Figure 2a ). Based on the 232 results of our adjuvant screen ( Supplementary Fig. 1 ), all the immunogens were 233 formulated in Alhydrogel, an adjuvant approved for human use. As compared to FFLM, 234 NRM showed a higher overall immunogenicity (directed both against RSVN and 235 FFLM) ( Figure 2b ). 236
237
A key aspect of epitope-focused vaccines is to understand how much of the antibody 238 response targets the viral epitope presented to the immune system. Therefore, we 239 sought to measure the site II-specific antibody titers elicited by NRM and FFLM and 240 compare these epitope-specific antibody responses to those elicited by prefusion 241 RSVF. Using an SPR competition assay to measure site II-specific antibodies in sera 242 (described in methods), we observed that NRM elicited site II-specific antibody 243 responses superior to those elicited by RSVF ( Figure 2c ). This was surprising, given 244 that the ratio of site II epitope surface area to overall immunogen surface is similar in 245 both NRM and RSVF ( Supplementary Fig. 2 ). To confirm this finding through a direct 246 binding assay rather than a competitive format, we measured the binding levels of 247 sera to the site II epitope in a peptide ELISA, where the site II peptide was immobilized 248 on streptavidin-coated wells. Consistent with the previous experiment, we found that 249 NRM elicited two orders of magnitude higher site II-specific responses than RSVF 250 ( Figure 2d ). Together, these data validated NRM as our lead immunogen to induce 251 high levels of site II-specific antibodies in mice. Given the substantial site II-specific serum titers elicited by NRM in mice, we 277 investigated whether these antibodies cross-reacted with prefusion RSVF and were 278 sufficient to neutralize RSV in vitro. 279
280
Following three immunizations with NRM, all the mice (n=10) developed detectable 281 serum cross-reactivity with prefusion RSVF (mean serum titer = 980) ( Figure 3a) . 282
Unsurprisingly, the overall quantity of prefusion RSVF cross-reactive antibodies 283 elicited by immunization with an immunogen presenting a single epitope is more than 284 two orders of magnitude lower than those of mice immunized with prefusion RSVF, 285 which comprises at least six antigenic sites (5). Similarly, a B-cell ELISpot revealed 286 that NRM-immunized mice presented prefusion RSVF-reactive antibody secreting 287 cells, but their frequency was approximately one order of magnitude lower than upon 288 immunization with prefusion RSVF (Figure 3c ). 289
290
The major determinant for antibody specificity is attributed to the heavy chain CDR3 291 region (HCDR3) (46). While for certain classes of nAbs, the antibody lineages and 292 their sequence features are well-defined (e.g. HIV neutralizing VRC01 class 293 antibodies (47), or RSV neutralizing MPE8-like antibodies (48)), antibodies targeting 294 RSV antigenic site II seem to be derived from diverse precursors and do not show 295 HCDR3 sequence convergence in humans (5). While we did not expect to find 296 dominant lineages or HCDR3 sequence patterns in mice, we used next-generation 297 antibody repertoire sequencing (49) to ask whether NRM could elicit antibodies with 298 similar sequence signatures to those elicited by prefusion RSVF. Indeed, we found 299 300 clonotypes, defined as antibodies derived from the same VH gene with the same 300 HCDR3 length and 80% sequence similarity, that overlapped between NRM and the 301 prefusion RSVF immunized cohort, suggesting that at the molecular level, relevant 302 antibody lineages can be activated with the NRM immunogen (Supplementary Figure  303 3). Notably, nine out of the 20 most expanded clonotypes in the NRM cohort were also 304 present in mice immunized with prefusion RSVF, albeit not as expanded ( Figure 3b ). 305
This finding might reflect the enrichment of site II specific antibodies in the NRM cohort 306 ( Figure 2d ). 307
308
We further investigated whether these low levels of prefusion RSVF-binding 309 antibodies were sufficient to neutralize RSV in vitro. While three immunizations with 310 prefusion RSVF elicited potent RSV-neutralizing serum titers (mean IC 50 = 10,827), for 311 NRM we only detected low levels of RSV-neutralizing serum activity in three out of ten 312 mice ( Figure 3d ). This result is consistent with Correia et al. (21) , who observed no 313 serum neutralization in mice, but succeeded in inducing nAbs in NHPs with prior RSV 314 seronegativity. 315
316
Altogether, we concluded that despite NRM's superior potential to induce high levels 317
of site II-specific antibodies, the majority of antibodies activated from the naïve 318 repertoire is unable to potently neutralize RSV in vitro. A potential explanation, 319 stemming from structural comparison between the epitope-focused immunogen 320 (FFLM) and RSVF, is that although epitope-specific antibodies are abundantly elicited 321 by NRM, these antibodies do not recognize the site II epitope in its native RSVF 322 quaternary environment in the prefusion conformation, or on virions in sufficient 323 amounts and with high enough affinity to potently neutralize RSV. indicates number of mice that showed the respective clonotype, width represents the 336 clonal expansion within a clonotype (i.e. the number of clones grouped into the 337 respective clonotype). Three clonotypes that occurred both in the RSVF and the NRM 338 cohort, but were expanded within the NRM cohort were analyzed for their HCDR3 339 sequence profile, as shown by sequence logo plots (top). Dark blue color represents 340 amino acid identities that occurred in RSVF cohort, light blue color represents amino 341 acids uniquely found following NRM immunization. The frequency of each amino acid 342 in the NRM cohort is indicated by the size of the letter. c) B-cell ELISpot of mouse 343 splenocytes to quantify prefusion RSVF-specific antibody secreting cells (ASC). We hypothesized that the high affinity of the epitope scaffold towards a panel of site 360 II-specific nAbs, together with the ability to elicit high titers of site II-specific antibodies 361 in vivo, could make the NRM an efficient immunogen to recall RSVF primed site II-362 specific B-cells, thereby achieving an enhanced and focused neutralization response. 363
364
Our initial homologous prime-boost immunization studies with prefusion RSVF 365 showed that site II-specific responses were subdominant (Figure 2c and 2d). Given 366 that subdominance is a common immunological phenotype for many of the 367 neutralization epitopes that are relevant for vaccine development (51), we sought to 368 test if NRM could boost subdominant site II-specific antibody lineages that should 369 ultimately be functional and recognize the epitope in the tertiary environment of 370 prefusion RSVF. To test this hypothesis, we designed a mouse immunization 371 experiment with three cohorts, as outlined in Figure 4a . Following a priming 372 immunization with RSVF, cohort (1) was boosted with adjuvant only ("prime only"), 373 cohort (2) received two boosting immunizations with prefusion RSVF ("homologous 374 boost"), and cohort (3) received two boosts with NRM ("heterologous boost"). 375
376
A comparison between prefusion RSVF immunized groups prime only and 377 homologous boost revealed that the two additional boosting immunizations with RSVF 378 only slightly increased overall titers of prefusion RSVF-specific antibodies (p = 0.02, 379
Mann-Whitney), indicating that a single immunization with adjuvanted RSVF is 380 sufficient to induce close to maximal serum titers against RSVF (Figure 4b ). Following 381 the heterologous boost with NRM, overall RSVF specific antibody titers remained 382 statistically comparable to the prime only group (p = 0.22, Mann-Whitney). 383 384 Next, we quantified the site II-specific endpoint serum titers in a peptide ELISA format 385 ( Figure 4c ). Interestingly, the homologous boost with prefusion RSVF failed to 386 increase site II-specific antibody levels, reducing the responses directed to site II to 387 the lower limit of detection by ELISA. This result is yet another example of the 388 underlying complexity inherent to the fine specificity of antibody responses elicited by 389 immunogens and how important specificities can be dampened throughout the 390 development of an antibody response. In contrast to the homologous boost, the 391 heterologous boost with NRM significantly increased site II peptide-specific serum 392 titers (p < 0.0001, Mann-Whitney). 393
394
In order to understand whether this increase relied at least partially on an actual recall 395 of antibodies primed by RSVF, or rather on an independent antibody response 396 irrelevant for RSVF binding and RSV neutralization, we dissected the epitope 397 specificity within the RSVF-specific serum response. In an SPR competition assay, a 398 significantly higher fraction (p = 0.02, Mann-Whitney) of prefusion RSVF-reactive 399 antibodies were competed by Motavizumab in mouse sera primed with prefusion 400 RSVF and boosted with NRM (mean % competition = 37.5 ± 14.5%), as compared to 401 mice immunized once or three times with prefusion RSVF (21.5% ± 12.1% or 19.5% 402 ± 3.7%, respectively) ( Figure 4d ). Similarly, a competition ELISA revealed that a 403 significantly larger fraction of overall RSVF reactivity was attributed to site II-specific 404 antibodies upon heterologous boost, as compared to both control groups (36.1% ± 405 2.5% versus 22.6% ± 9.1% or 14.4% ±5.9%, respectively, p = 0.002 and p < 0.0001, 406
Mann-Whitney). In contrast, site II-specific antibodies were significantly higher in mice 407 that received only one as opposed to three RSVF immunizations, indicating that RSVF 408 boosting immunizations depleted site II-specific antibody titers (p = 0.03, Mann-409 Whitney) ( Figure 4e ). 410 411 Together, we have shown that the serum antibody specificity can be steered towards 412 antigenic site II by boosting with NRM under conditions of pre-existing immunity, and 413 thereby increase site II-specific antibody levels in vivo. This is an important and 414 distinctive feature of NRM compared to prefusion RSVF, which was shown to 415 decrease Palivizumab-like antibody responses under the same conditions. These 416 results may have broad implications on strategies to control antibody fine specificities 417 in vaccination schemes, both for RSV and other pathogens. The enhanced reactivity to site II observed in the heterologous prime-boost scheme 458 led us to investigate if changing the nature of the immune response had functional 459 consequences upon RSV neutralization. Overall, we observed 2.3-fold higher serum 460 neutralization titers in mice receiving a heterologous boost (mean IC 50 =7654) 461 compared to the prime only control group (mean IC 50 =3275) (Figure 5a ). While the 462 neutralization titer difference in these two groups (prime vs. heterologous boost) did 463 not reach statistical significance, the homologous prime boost was significantly 464 improved relative to the prime only (mean IC 50 = 10,827 vs mean IC 50 = 3,276) and 465 interestingly, we also did not observe a statistically significance between the 466 homologous boost and the heterologous boost cohort (mean IC 50 = 10,827 vs. mean 467 IC 50 = 7,654). 468
469
Next, we assessed if this increase in neutralization was driven by increased levels of 470
Palivizumab-like antibodies. We observed that site II-directed antibody levels 471 correlated with overall serum neutralization titers in the heterologous prime boost 472 group (r 2 =0.76, p=0.0009) (Figure 5b ), whereas prime only (r 2 =0.32, p=0.09) or 473 animals receiving a homologous boost showed no such correlation (r 2 = 0.18, p=0.22) 474 ( Supplementary Figure 4) . To characterize the neutralizing serum activity dependence 475 on antigenic site II, we pooled mouse sera within each cohort, enriched site II-specific 476 antibodies and measured neutralization (see methods). Briefly, we incubated pooled 477 sera from each group with streptavidin beads conjugated to biotin-labeled antigenic 478 site II peptide, and eluted bound antibodies. To control for the quality of the enrichment 479 protocol, we verified by ELISA that the column flow-through was depleted of site II-480 specific antibodies (Supplementary Figure 5) . 481 482 Strikingly, mice receiving a heterologous boost showed a 15-fold increase in site II-483 mediated neutralization as compared to mice immunized once or three times with 484 prefusion RSVF (Figure 5c ). We performed the same experiment for mice immunized 485 three times with NRM and did not detect any RSV neutralization in this format. This Epitope scaffolds have been shown to hold great potential to elicit RSV antigenic site 530 II-specific, neutralizing antibody responses in naïve non-human primates, and an 531 elicited monoclonal antibody showed superior neutralization potency to that of 532 Palivizumab (21). However, a major limitation of epitope scaffolds or peptide-based 533 vaccine approaches (54-56) is that the quaternary environment of the epitope in its 534 viral protein is lost, and thereby the binding mode of a significant fraction of the 535 antibodies elicited is likely incompatible with the epitope in its native environment. This 536 observation is reinforced by our finding that although NRM elicited high serum levels 537 of site II-directed antibodies, only residual RSV neutralizing activity was observed, 538 which is consistent with the results of several previous studies using epitope scaffolds 539 (56-58). This presents a major limitation to the use of synthetic scaffolds in an epitope-540 focused vaccine approach in naïve individuals. 541 542 However, some of the most relevant target populations for RSV vaccination (both 543 pregnant women and the elderly) have pre-existing humoral responses against RSVF, 544
including to site II (59). To date, boosting nAbs targeting specific epitopes under 545 conditions of pre-existing immunity has proven challenging, particularly because a 546 strong antibody response against immunodominant epitopes that structurally surround 547 a subdominant neutralization epitope can sterically mask the neutralization epitope, 548 preventing a subdominant epitope from mounting a potent antibody response (27, 29, 549 30, 60) . Overcoming immunodominance hierarchies under conditions of pre-existing 550 immunity has proven challenging both for RSV, Influenza, and others, and such 551 hierarchies seem to be impacted by multiple factors including serological antibody 552 levels, their specificity, memory B-cell counts, adjuvants, as well as the immunization 553 or infection route (28). While this scenario may not be fully absent in the synthetic epitope-scaffolds, it is at 565 least mitigated by the fact that the protein has not evolved under the pressure of 566 escaping the immune system. 567
568
Another key aspect in heterologous prime-boost schemes is to maintain the structural 569 integrity of the neutralizing epitope in both the priming and heterologous boosting 570 immunogens. FFL_001 has been thoroughly structurally characterized and presents 571 a very close mimicry of the site II epitope in RSVF (21). Importantly, a recent study by 572
Mousa et al. (61) has identified non-neutralizing antibodies that can compete with 573
Palivizumab by binding to a nearby epitope, and a large-scale sequence analysis has 574 suggested that the presence of similar antibodies may be common in the human RSV 575 immune response. However, as the site II epitope scaffold does not contain this non-576 neutralizing site, their study demonstrated that FFL_001 can distinguish site II nAbs 577 from their non-neutralizing competitors (61). Using an extended panel of site II specific, 578 potent nAbs, we could confirm that the epitope scaffold binds with extremely high 579 affinity to multiple site II nAbs, leading us to speculate that NRM could recall site II-580 specific memory B-cells in vivo, thereby boosting site II-specific serum titers. Given 581 the very low serum titers specific for antigenic site II following a prefusion RSVF prime, 582 it was questionable whether NRM could boost these subdominant antibody levels. 583
However, previous studies with HIV immunogens have shown that a very low number 584 of epitope-specific B-cells (1 out of 1,000,000) is sufficient to be selected and recruited 585 to the germinal center by a multimeric immunogen that binds with high affinity to the 586 target B-cell receptor (57). Indeed, we found that under conditions where site II-587 specific antibodies are subdominant, a heterologous boost can redirect serum 588 antibody specificity towards increased site II recognition. Importantly, these antibodies 589 competed with Motavizumab for RSVF binding, confirming their recognition of the 590 epitope in its native quaternary context. In contrast, repeated immunization with 591 prefusion RSVF failed to direct antibodies towards antigenic site II. 592
593
This study demonstrates that the number of neutralization epitopes in a heterologous 594 boosting immunogen can be reduced to a single, well-defined site; which, if the 595 immunogen is optimally presented, can enhance pre-existing, subdominant antibody 596 responses targeting this epitope. The ability to narrowly focus antibody responses to 597 a single, well-understood epitope that mediates clinical protection once it is targeted 598 by sufficient antibody titers is an important milestone for RSV vaccine development. 599 600 Given that this approach is generalizable and that epitope scaffold nanoparticles have 601 proven successful in boosting nAbs specific for other sites, this strategy holds great 602 potential to tune levels of antibody specificities depending on the target population. 603
Goodwin et al. have shown that young infants preferentially develop RSV site III-604
specific antibodies that lack somatic hypermutation (48). Consequently, vaccine 605 antigens given to pregnant women should primarily induce antibodies targeting 606 structurally distal antigenic sites in order to avoid interference with an immune 607 response mounted by the infant. Given these specific antibody lineage requirements 608 and the previously failed clinical trial in infants (62), its seems unlikely that a vaccine 609 based solely on prefusion RSVF could be maximally effective in all target populations. 610
The addition of precision immunogens to spotlight different antigenic sites tailored to 611 a specific patient population may increase the efficacy of prefusion RSVF-based 612
vaccines. An increasing structural and immunological understanding of antibody 613 specificities will help inform the design of novel immunogens and appropriate 614 immunization regimens, allowing the tailoring of vaccine-induced antibody responses 615 in different target populations. 616 617 However, our results show that the success of this boosting strategy is dependent on 618 the presence of a low but detectable amount of site II-specific antibodies elicited by 619 prefusion RSVF. Although three immunizations with NRM yielded even higher site II 620 peptide-specific antibodies, these antibodies were largely non-neutralizing. Further 621 studies in more relevant animal models will reveal if natural infection with RSV can 622 also serve as appropriate prime for subsequent boosting of site II-nAbs, as well as for 623 other RSV neutralization epitopes. 624
625
Projecting beyond the RSV vaccine problem, these results provide a strong rationale 626
for developing precision immunogens that present conserved, neutralization-sensitive 627 sites of other pathogens. For example, multiple epitopes on the Influenza 628 hemagglutinin head and stem region that confer broad and potent antibody-mediated 629 neutralization have been identified. Focusing antibody responses on these defined 630 epitopes may remove the need for annual vaccine reformulation, and may also protect 631 against emerging pandemic strains (14, 51, 63, 64) . The Influenza vaccine challenge 632 seems particularly well suited to our approach considering that the human population 633 has pre-existing immunity to Influenza, including some subdominant bnAbs that subtypes and Zika envelope protein has been structurally characterized and 639 suggested for the development of an epitope-focused immunogen (7). 640
641
When seeking to apply an immunofocusing strategy to other antigenic sites and 642 pathogens, one challenge is the development of epitope scaffolds stably presenting 643 the epitope in a synthetic immunogen that is compatible with antibody binding. While 644 the RSV antigenic site II is a structurally simple helix-turn-helix motif, many other 645 identified neutralization epitopes comprise multiple, discontinuous segments. 646
However, continuous advances in rational protein design techniques (66) will allow the 647 design of more complex protein scaffolds to stabilize increasingly complex epitopes. 648 649 Altogether, we have shown the development of an optimized RSV epitope scaffold 650 nanoparticle able to boost subdominant, neutralizing antibody responses in vivo that 651 target site II, an epitope of utmost clinical relevance. This is a distinctive feature 652 compared to using prefusion RSVF as a boosting immunogen, and underscores how 653 subdominant epitopes can be converted to immunodominant epitopes when 654 presented in a different environment. We foresee the great promise of this strategy to 655 overcome the challenge of boosting and focusing pre-existing immunity towards 656 defined neutralization epitopes, potentially applicable to multiple pathogens. 657
658
Methods 659
660
Resurfacing 661
The previously published RSV site II epitope scaffold ("FFL_001") (21) was designed 662 based on a crystal structure of a mutant of ribosome recycling factor from E. coli (PDB 663 entry 1ISE. Using BLAST, we identified sequence homologs of 1ISE from eukaryotic 664 organisms and created a multiple sequence alignment with clustal omega 665 system (GE healthcare). Bound proteins were eluted in buffer containing 50 mM Tris, 686 500 mM NaCl and 300 mM imidazole, pH 7.5. Concentrated proteins were further 687 purified by size exclusion chromatography on a Superdex TM 75 300/10 (GE 688 Healthcare) in PBS. Protein concentrations were determined via measuring the 689 absorbance at 280 nm on a Nanodrop (Thermo Scientific). Proteins were concentrated 690 by centrifugation (Millipore, #UFC900324) to 1 mg/ml, snap frozen in liquid nitrogen 691 and stored at -80°C. The antigenic site II was synthesized as peptide by JPT Peptide Technologies, 796
Germany. The following sequence was synthesized and biotinylated at the N-797 terminus: 798
MLTNSELLSKINDMPITNDQKKLMSNNVQI 799
For ELISA analysis of peptide-reactive serum antibodies, Nunc MediSorp plates were 800 coated with 5 µg/ml streptavidin (Thermo Scientific, #21122) for one hour at 37°C. 801
Subsequently, ELISA plates were blocked as indicated above, followed by the addition 802 of 2.4 µg/ml of the biotinylated site II peptide. Coupling was performed for one hour at 803 room temperature. The subsequent steps were performed as described for the antigen 804
ELISA. 805 806

Serum competition using Surface Plasmon Resonance 807
Approximately 300 RU of antigen were immobilized via amine coupling on a CM5 chip. 808
Mouse sera were diluted 1:100 in HBS-EP+ running buffer and flowed as analyte with 809 a contact time of 120 seconds to obtain an initial response unit (RU non-blocked surface ). 810
The surface was regenerated using 50 mM NaOH. Sequentially, Motavizumab was 811 injected four times at a concentration of 2 µM, leading to complete blocking of 812 (Gibco, #11875093) supplemented with 10% FBS (Gibco), Penicillin/Streptomycin 832 (Gibco), 0.01 µg/ml IL2, 1 µg/ml R848 (Mabtech, #3825-2H) and 50 µM β-833 mercaptoethanol (Sigma) for ~60 hours stimulation at 37 °C, 5% CO 2 . ELISpot plates 834 (PVDF 96-well plates, Millipore, #MSIPS4510) were coated overnight with 15 µg/ml 835 antigen diluted in PBS, followed by careful washing and blocking using RPMI + 10% 836 FBS. Live splenocytes were counted and the cell number was adjusted to 1x10 7 837 cells/ml. Serial dilutions of splenocytes were plated in duplicates and incubated 838 overnight with coated plates. After several wash steps with PBS buffer, plates were 839 incubated for two hours with biotinylated anti-mouse total IgG (Mabtech, # 3825-6-840 250) in PBS, followed by incubation with streptavidin-conjugated to HRP (Mabtech, 841 #3310-9) for one hour. Spots were revealed using tetramethylbenzidine (TMB, 842
Mabtech, #3651-10) and counted with an automatic reader (Bioreader 2000; BioSys 843
GmbH). Results were represented as number of spots per 10 6 splenocytes. 844
845
RSV neutralization assay 846
The RSV A2 strain carrying a luciferase gene (RSV-Luc) was a kind gift of Marie-Anne 847
Rameix-Welti, UFR des Sciences et de la Santé, Paris. Hep2 cells were seeded in 848
Corning 96-well tissue culture plates (Sigma, #CLS3595) at a density of 40,000 849 cells/well in 100 µl of Minimum Essential Medium (MEM, Gibco, #11095-080) 850 elution buffer (0.1 M glycine, pH 2.7) and incubated for 1 minute before centrifugation. 884
Supernatant was removed, neutralized with 40 µl neutralization buffer (1 M Tris pH 885 7.5, 300 mM NaCl), and stored at -20 °C for subsequent testing for RSV neutralization. 886
As a control, unconjugated streptavidin was used for each sample to account for non-887 specific binding. 888 889 Next-generation antibody repertoire sequencing (NGS) 890
RNA isolation 891
Mouse bone marrow was isolated from femurs and re-suspended in 1.5 ml Trizol (Life 892 Technologies, #15596) and stored at -80˚C until further processing. RNA extraction 893 was performed using the PureLink RNA Mini Kit (Life Technologies, #12183018A) 894 following the manufacturer guidelines. 895 896 Antibody sequencing library preparation 897
Library preparation for antibody variable heavy chain regions was performed using a 898 protocol that incorporates unique molecular identifier (UID) tagging, as previously 899 described in Khan et al. (70) . Briefly, first-strand cDNA synthesis was performed by 900 using Maxima reverse transcriptase (Life Technologies, #EP0742) following the 901 manufacturer instructions, using 5 µg RNA with 20 pmol of IgG gene-specific primers 902 (binding IgG1, IgG2a, IgG2b, IgG2c, and IgG3) with an overhang of a reverse UID 903 (RID). After cDNA synthesis, samples were subjected to a left-hand sided SPRIselect 904 bead (Beckman Coulter, #B23318) cleanup at 0.8X. Quantification of target-specific 905 cDNA by a digital droplet (dd)PCR assay allowed exact input of 135000 copies into 906 the next PCR step. Reaction mixtures contained a forward multiplex primer set that 907 was specific for variable heavy region framework 1 and possessed forward UID (FID), 908 a 3' Illumina adapter specific reverse primer, and 1X KAPA HIFI HotStart Uracil+ 909
ReadyMix (KAPA Biosystems, #KK2802). PCR reactions were then left-hand side 910
SPRIselect bead cleaned as before and quantified using ddPCR assay. Finally, an 911
Illumina adaptor-extension PCR step was carried out using 820000 copies of the 912 previous PCR product. Following 2nd-step adaptor-extension PCR, reactions were 913 cleaned using a double-sided SPRIselect bead cleanup process (0.5X-0.8X) and 914 eluted in TE buffer. 915 916 NGS with Illumina MiSeq (2 x 300 bp) 917
After library preparation, individual NGS libraries were characterized for quality and 918 quantified by capillary electrophoresis using a Fragment Analyzer (Advanced 919
Analytical DNF-473 Standard Sensitivity). Samples were then pooled and NGS was 920 performed on the Illumina MiSeq platform with a MiSeq Reagent Kit V3, 2x300bp 921 paired-end (Illumina, #MS-102-3003), using an input concentration of 10 pM with 10% 922
PhiX. 923 924
Error and bias correction 925
Error and bias correction was performed using molecular amplification fingerprinting 926 pipeline, as previously described (70, 71). 927
1) Bioinformatic preprocessing 928
Paired-end FASTQ files obtained from Illumina MiSeq were imported into CLC 929 Genomics Workbench 10 on the ETH Zurich Euler High Performance Computing 930 (HPC) cluster. A preprocessing workflow was run containing the following steps: 931 trimming of low quality reads, merging of paired-end reads, removal of sequences not 932 aligning to mouse IGH constant sequences, and length filtering. 933 934 2) Error correction by consensus building 935
After pre-processing all datasets were downsampled to contain the same amount of 936 sequencing reads as the dataset with the lowest overall number of reads (361749 937 sequencing reads). For error correction, a custom Python script was used to perform 938 consensus building on the sequences for which at least three reads per UID were 939 required. VDJ annotation and frequency calculation was then performed by our in-940 house aligner (70, 71). The complete error-correction and alignment pipeline is 941 available under https://gitlab.ethz.ch/reddy/MAF. 942 943
Sequence analysis and data visualization 944
Data analysis was done by customized scripts in R. For the identification of clonotypes 945 hierarchical clustering (71) was utilized to group CDR3 sequences together. The 946 following parameters were used: identical IGHV and IGHJ gene segment usage, 947 identical CDR3 length, and at least 80% CDR3 amino acid similarity to one other 948 sequence in the given clonotype (single linkage). The overlap of clonotypes between 949 both cohorts was analyzed by extracting the 20 most expanded clonotypes from each 950 cohort and visualizing their size, occurrence, and Vgene usage by a circos plot using 951 R software circlize (72). CDR3 sequence similarities between overlapping clonotypes 952 were represented graphically with the R software motifStack (73). Scripts used for 953 analysis are available under https://github.com/luciacsep/EpitopeFocussing. 954 955
Data availability 956
Data supporting the findings of this study are available within the article and its 957
Supplementary Information, or are available from the authors upon request. 
